Correspondence 0001104659-24-077357 from Kiniksa Pharmaceuticals International, plc (KNSA) (CIK 0001730430) (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA) (CIK 0001730430)
Date: July 2, 2024 · CIK: 0001730430 · Accession: 0001104659-24-077357
AI Filing Summary & Sentiment
File numbers found in text: 333-280611
Letter
Re: Kiniksa Pharmaceuticals International, plc
July 2, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jason Drory
Registration Statement on Form S-3
Filed June 28, 2024
Registration No. 333-280611
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement on Form S-3 so that it will become effective on July 3, 2024 at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Kiniksa Pharmaceuticals International, plc (the “Company”) or its counsel may request via telephone call to the staff. Please contact Marko Zatylny of Ropes & Gray LLP, counsel to the Company, at (617) 951-7980 to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Very truly yours,
KINIKSA PHARMACEUTICALS
Show Raw Text
CORRESP
1
filename1.htm
July 2, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jason Drory
Re:
Kiniksa Pharmaceuticals International, plc
Registration Statement on Form S-3
Filed June 28, 2024
Registration No. 333-280611
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation
C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective
date of the above-referenced Registration Statement on Form S-3 so that it will become effective on July 3, 2024 at 4:00 p.m.,
Eastern Time, or as soon thereafter as practicable, or at such later time as Kiniksa Pharmaceuticals International, plc (the “Company”)
or its counsel may request via telephone call to the staff. Please contact Marko Zatylny of Ropes & Gray LLP, counsel to the
Company, at (617) 951-7980 to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Very truly yours,
KINIKSA PHARMACEUTICALS
INTERNATIONAL, PLC
/s/ Madelyn Zeylikman
Madelyn Zeylikman
General Counsel
cc: Sanj K. Patel, Chief Executive Officer, Kiniksa Pharmaceuticals
International, plc
Timothy Perdew, Senior Director, Senior Corporate
Counsel, Kiniksa Pharmaceuticals International, plc
Paul Kinsella, Ropes & Gray LLP
Marko Zatylny, Ropes & Gray LLP
T: (781) 431-9100
23 Old Bond St. London, UK W1S 4PZ